Teva Pharmaceuticals Europe: Patients Search for Information Online – but Aren’t Sure If They Can Trust What They Find
Recent research commissioned1 by Teva Pharmaceuticals has shown that patients, especially those with chronic conditions, have a significant need for online information but they question the reliability of some sources.1
Today, Teva in Europe announced a series of partnerships and initiatives aimed at directly addressing this unmet need. The first, a partnership with Healint, the developer of the Migraine Buddy© platform, will provide real-world evidence about the many issues and outcomes experienced by migraine patients in Europe. These statistical insights produced by Healint on their platform are based on the contributions of patients, who opt-in to share about their condition anonymously for the purpose of increased migraine awareness, and research. This patient-reported evidence with an unprecedented scale will support the generation of educational and supportive content for doctors, neurologists, health specialists and individuals looking to enhance their understanding of migraine.
Recent research in the professional field highlights the growing interest by medical professionals in digital assets to support their continuous education needs and day-to-day work. A 2017 DRG Digital report found that millennial physicians are more reliant on digital sources of information spending as much as three hours consulting external digital resources including websites for healthcare professionals. They source online medical journals and medical reference sites far more frequently than their older peers.2
To address this professional need Teva is working with Migraine Trust International Symposium (MTIS) to create engaging online interviews with leaders in the field of neurology including Professor of Neurology at King's College London and Medical Trustee of The Migraine Trust, Peter J. Goadsby on the subject of ‘Recent advances in headache neuroimaging’. These videos and content will be made available through the MTIS website for UK delegates and on NeurologyBytes.com for non-UK delegates.
Neurology Bytes is a European Healthcare Professional portal initiated by Teva Europe that hosts a variety of educational content that complements the busy schedule of a neurologist and addresses the unmet need for reliable and trustworthy information.
CEO and Co-Founder of Healint, Francois Cadiou commends Teva’s efforts to provide independently reviewed information to support healthcare professionals in becoming more knowledgeable about migraine. “Our collaboration with Teva aims to support healthcare professionals to understand migraine patients better, so that they can obtain the most effective care plan faster. We at Healint are happy to support this transformative initiative with the unique data analysis carried out on the Healint platform. This fact-based information and our collaboration with Teva provides significant benefits to the entire migraine community.”
Professor of Neurology at King's College London and Medical Trustee of The Migraine Trust, Peter J. Goadsby MD PhD stated: “Migraine is a complex condition which requires broader disease awareness in order for patients to communicate effectively about their condition. Patients often need to be their own advocates given the significant amount of patient information doctors require to diagnose and treat their conditions. I welcome Teva’s initiatives which aim to support both the patient and the medical community through reliable and trustworthy information. I hope this initiative creates a better dialogue between patients and their doctors so they can determine the best course of treatment for this debilitating condition.”
Teva Head of Digital, Timothy White said: “Teva is committed to empowering patients and professionals around the world through their health journey, especially those living with or treating chronic conditions such as migraine, by providing high quality medicines as well as tools based on human insights. Our partnerships with MTIS and Healint as well as the growth of our Neurologybytes.com platform demonstrate the practical ways of how we are bringing the vision to life.”
About the Research
The research (2018) found:
- 7 in 10 people (73%) in the UK have a chronic condition and online resources continue to be sought with over half (58%) of UK respondents with chronic conditions claiming to have searched for information on a weekly or monthly basis1
- People living with chronic conditions were more likely to search for health information online on a weekly or monthly basis (58%) compared to those without chronic conditions (44%)1
- The biggest issue that the UK faces in relation to online health information is understanding if it is trustworthy and reliable1
- Search engines are the most popular online source of health information but not the most trusted. For example, in the UK, the NHS Choices website is the most trusted source of information with 3 out of 4 (75%) of respondents stating they trust the site to have quality and dependable information1
Migraine is an unpredictable neurological condition with symptoms such as severe head pain and physical impairment that can impact quality of life and productivity.3 There are two clinical manifestations of migraine – chronic, where patients suffer 15 or more headache days per month, and episodic, where patients have 14 or less headache days per month.4 With more than 1 billion people affected worldwide, migraine is the third most prevalent illness in the world.3
1. Edelman Intelligence 2018. Teva Brand Research - UK information
2. Meet the Millennial Physicians – Young, Mobile, and Harder to Reach. DRG Digital. Available at: https://www.drgdigital.com/drg-digital-innovation-blog/meet-the-millennial-physicians-young-mobile-and-harder-to-reach. Accessed 31.08.18
3. Migraine Research Foundation, Migraine Facts. Available at: http://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed 31.08.18
4. Adapted from American Migraine Foundation. Available at: https://americanmigrainefoundation.org/understanding-migraine/chronic-migraine/. Accessed 31.08.18
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
Healint helps the one billion people who suffer from migraine and other neurological conditions and is the developer of the world’s largest migraine tracking and research platform Migraine Buddy©. With more than one million registered users and 100 million migraine days tracked on the platform, Migraine Buddy© is the most popular condition-specific app in the world, and a Top 10 medical app in the USA and Europe. Using deep analytics and machine learning, Healint generates real-world evidence for patients, physicians, and researchers to improve treatment outcomes and expedite clinical trials. Healint collaborates with the world's leading scientists to improve the diagnosis, treatment, and lives of patients suffering from multiple neurological conditions. For more information, visit: www.healint.com.
Date of Preparation: September 2018 | Ref: UK/CPE/18/0065
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Piraeus Bank Presents the Principles for Responsible Banking with the Governor of the Bank of Greece16.1.2019 18:21 | Pressemelding
The Principles for Responsible Banking were presented today for the first time in Greece at an event organized by Piraeus Bank with Mr. Yannis Stournaras, the Governor of the Bank of Greece, as the keynote speaker. The event was organised as part of Piraeus Bank’s commitment to the United Nations Environment Programme Finance Initiative (UNEP FI). Piraeus is the only Greek bank to be a member of the global initiative, which includes twenty-eight banks from around the world, representing over USD 17 trillion in combined assets. Mr. Yannis Stournaras, the Governor of Bank of Greece, highlighted in his speech that the Bank of Greece fully supports the Principles for Responsible Banking and urges all of the banks to endorse the Principles and set ambitious targets. The Bank of Greece was one of the first central banks to become involved with the climate change issue, establishing the Climate Change Impacts Study Committee in 2009 and investing in one of the most significant Sustainable Dev
Arrowgrass Has Agreed to an Extension of Its Irrevocable Undertaking Regarding Its Holdings in Basware Corporation16.1.2019 17:30 | Pressemelding
The investment funds of Arrowgrass Capital Partners LLP (“Arrowgrass”) hold, directly and indirectly, over 24 per cent of all shares and votes in Basware Corporation (“Basware”), a Finnish listed company providing networked source-to-pay solutions and e-invoicing services. Arrowgrass refers to the announcements made by Basware on 16 November 2018, 20 November 2018 and 7 December 2018 with regard to a possible tender offer by Tradeshift Holdings Inc. (“Tradeshift”) for Basware. Arrowgrass announces that it has agreed, under certain conditions, to extend an irrevocable undertaking with Tradeshift to accept a tender offer by Tradeshift for Basware, should Tradeshift publicly announce its tender offer in accordance with applicable laws and regulations no later than 28 February, 2019. Arrowgrass recognizes that Basware has emphasized in its announcements that the launch of the tender offer remains uncertain. About Arrowgrass Arrowgrass Capital Partners LLP is a London headquartered alternat
PCI Security Standards Council Publishes New Software Security Standards16.1.2019 15:25 | Pressemelding
Today, the PCI Security Standards Council (PCI SSC) published new requirements for the secure design and development of modern payment software. The PCI Secure Software Standard and the PCI Secure Lifecycle (Secure SLC) Standard are part of a new PCI Software Security Framework, which includes a validation program for software vendors and their software products and a qualification program for assessors. The programs will be launched later in 2019. “Innovation in payments is moving at an incredible pace. Each advancement provides the industry the opportunity to develop applications more quickly and efficiently than before and to design software for new platforms for payment acceptance,” said PCI SSC Chief Technology Officer Troy Leach. “The new PCI Secure Software Standard and PCI Secure SLC Standard support this evolution in payment software practices by providing a dynamic way for developers to demonstrate their software protects payment data for the next generation of applications.”
Keio Plaza Hotel Hosts “Hina-matsuri (Girls’ Doll Festival)” Event – 6,800 Magnificent Hanging Art Ornaments and Tea Ceremony Culture16.1.2019 14:05 | Pressemelding
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host an event entitled “Hina-matsuri through Tea Ceremony Culture and Hanging Art” to help guests celebrate Japan’s cultural event known as Girls’ Doll Festival or “Hina-matsuri” from February 1 (Friday) to March 28 (Thursday), 2019 with magnificent hanging art ornaments displayed in our lobby and special menu items served in our restaurants. In addition to the display of some 6,800 magnificent and ornate handmade dolls and other traditional decorations in this coming event, our Hotel will also display various traditional and historical art items used in traditional Japanese tea ceremony, which has long been a part of the cultural upbringing of Japanese women from the Meiji Period (1868 to 1912). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005191/en/ About 6,800 hanging decorative art ornaments meticul
Virgin Voyages Calling All RockStars to Sea16.1.2019 14:00 | Pressemelding
Virgin Voyages, the new lifestyle brand set to disrupt the travel industry, today released several designs and images of their RockStar Suites. The new company is throwing out traditional clichés on luxury and formalities, and instead bringing Rebellious Luxe to life at sea with their RockStar Suites designed by Tom Dixon’s Design Research Studio as the pinnacle of that experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005444/en/ Massive Suite Living Room. (Photo: Business Wire) Highlights of the Massive Suite, the top suite aboard the Scarlet Lady, include its very own guitar-clad music room, views of the ocean from every corner of the suite, and a massive terrace complete with its own Peek-a-View outdoor shower, hot tub, hammocks and a runway outdoor dining table, where a staircase will help Sailors make their way on top of the table for dancing. “Virgin has always avoided stuffy formalities and brought a lo
Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease16.1.2019 13:24 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. The EC approval is based on data from the pivotal Phase 3 SPARTAN study, which was published in The New England Journal of Medicine. The study assessed the efficacy and safety of apalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with nmCRPC who had a rapidly rising prostate specific antigen (PSA) level despite receiving continuous ADT. Findings from the study showed that apalutamide plus ADT, significantly reduced the risk of developing distant metastasis or death (metastasis free survival [MFS]) by 72 percent, compared to placebo in combination with ADT (HR = 0.28; 95% CI, 0